Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials

Integrating breast cancer genomics and proteomics

Next wave of successful drug therapy strategies in HER2-positive breast cancer

Genetic and clinical factors best for predicting late recurrence in oestrogen receptor positive breast cancer

CD4 T cells in extensively inflitrated breast cancer signal organised immune response and predict survival

How do we design trials that improve outcome?

Breast cancer heterogeneity no barrier to predictive testing

Single cell sequencing techniques in early and late breast cancer

Measurement variation influences gene expression profiles of breast cancer

The future of PI3K/AKT/mTOR inhibitors in breast cancer

Extracellular matrix proteins of stem cell niches promote breast cancer metastasis

Early effect of PI3K-Akt-mTOR blockade on in vitro 18F-FDG uptake in HER2 breast cancer resistant to trastuzumab

Update on the METABRIC consortium 2000 Breast Cancer Study

The Cancer Genome Atlas (TCGA): comprehensive molecular portraits of breast cancer

Genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer

Gene expression test distinguishes between breast cancer patients at high or low risk of late recurrence

Long-term effectiveness of SERMs for preventing breast cancer